Manuscripts
Showing 1543 manuscripts.
Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children
Citation
P Muresan, C Luongo, C Cunningham, P Collins, J Libous, U Buchholz, C Perlowski, IMPAACT 2011 Study Team, B Thumar, D Gnanashanmugam, J Moye, E Schappell, E Barr, V Rexroad, L Fearn, S Spector, M Aziz, M Cielo, E McFarland, C Beneri, R Karron, A Wiznia. Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. Journal of Infectious Diseases. 2020. 221: 534-543. PMID: 31758177Year
2020
Journal
Journal of Infectious Diseases
Study
IMPAACT 2011
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial
Citation
Mark Mirochnick, Patricia M Flynn, Kevin Butler, Jennifer J Kiser, George K Siberry, Terry Fenton, Mae Cababasay, Mary G Fowler, PROMISE Study Team, Jim Aizire, Kristina Brooks. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. Journal of Acquired Immune Deficiency Syndromes. 2020. 83: 173-180. PMID: 31929405Year
2020
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
1077BF
Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors
Citation
D Yin, C Ludema, S Cole, C Golin, W Miller, M Warshaw, R McKinney ; on behalf of the PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. PLoS One. 2020. 15: e0242405. PMID: 33226999Year
2020
Journal
PLoS One
The neovaginal microbiome of transgender women post-gender reassignment surgery
Citation
C Zuend, S Mutch, L Noel-Romas, A Lamont, M Abou, E Jalil, V Veloso, B Grinsztejn, R Friedman, K Broliden, F Bradley, V Poliquin, F Li, C Yanavich, K Birse, A Burgener, K Kratzer, G Aldrovandi. The neovaginal microbiome of transgender women post-gender reassignment surgery. BMC Microbiome. 2020. 8: 61. PMID: 32370783Year
2020
Journal
BMC Microbiome
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)
Citation
Mae Cababasay, Jiajia Wang, Anne Chain, Hedy Teppler, Stephanie Popson, Bobbie Graham, Betsy Smith, Rohan Hazra, Kat Calabrese, Yvonne Bryson, Stephen Spector, Jos Lommerse, Mark Mirochnick, IMPAACT P1110 Protocol Team, Diana Clarke, Edward Acosta. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 2020. 84: 70-7. PMID: 31913995Year
2020
Journal
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Study
P1110
Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy
Citation
Khadija Amin, David E Shapiro , Alice Stek , Elizabeth Smith, Nahida Chakhtoura, Michael Basar, Kathleen George, Katherine M Knapp, Esaú C João, Kittipong Rungruengthanakit , Edmund Capparelli, Sandra Burchett , Mark Mirochnick , Brookie M Best, Ahizechukwu C Eke, P1026s Protocol Team, Jiajia Wang. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrobial Agents and Chemotherapy. 2020. 64: e02260-19. PMID: 32015036Year
2020
Journal
Antimicrobial Agents and Chemotherapy
Study
P1026S
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
Citation
Zaakirah Essack , David E Shapiro, Timothy R Cressey, Nahida Chakhtoura, Kulkanya Chokephaibulkit, Maria Isabel S Gouvèa, Peerawong Werarak, Maria de Lourdes B Teixeira, Lauren Laimon, Trevon L Fuller, Roslyn Hennessy , Blandina T Mmbaga, Lisa M Frenkel , James S Ngocho, Patricia Anthony, Boniface N Njau, Brookie M Best, Avy Violari, George K Siberry, Ruth Mathiba, Mark Mirochnick, Jose Henrique S Pilotto, Luis Felipe Moreira, Maria Jose Rolon, Esaú C João, Pedro Cahn, R Leavitt Morrison, Sinart Prommas. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. Lancet HIV. 2020. 7: e322-e331. PMID: 32386720Year
2020
Journal
Lancet HIV
Study
P1081
Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with SH non-coding region is highly immunogenic in children
Citation
Petronella Muresan, Peter L.Collins, Coleen K. Cunningham, Ursula J. Buchholz, Charlotte Perlowski, Jennifer Libous, Jennifer Oliva, Patrick Jean-Philippe, Jack Moye Jr, Elizabeth Schappell, Emily Barr, Vivian Rexroad, Laura Fearn, Mikhaela Cielo, Andrew Wiznia, Jaime G. Deville, Elizabeth J. McFarland, Lijuan Yang, Ruth A. Karron, Cindy Luongo. Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with SH non-coding region is highly immunogenic in children. Journal of Infectious Diseases. 2020. 221: 2050-2059. PMID: 32006006Year
2020
Journal
Journal of Infectious Diseases
Study
IMPAACT 2013
Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age
Citation
Catherine Gordon, Rohan Hazra, Hans Spiegel, Flavia Ferreira, Fabiana R Amaral, Jesica Pagano-Therrien, Aditya Gaur, Kathy George, jane Benson, George K Siberry, Denise L Jacobson, Jane C Lindsey. Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clinical Infectious Diseases. 2020. 71: 1281-1288. PMID: 31573608Year
2020
Journal
Clinical Infectious Diseases
Study
P1076
Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda
Citation
Lillian Wambuzi Ogwang, Rachel Kawalazira, Alex Mutebe, Itziar Familiar-Lopez, MacPherson Mallewa, Taha Taha, Michael J Boivin, Mary Glenn Fowler, Jim Aizire, Alla Sikorskii, PROMISE NEURODEV Study Team. Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda. AIDS. 2020. 34: 215-225. PMID: 31634154Year
2020
Journal
AIDS
Study
1077BF